Cardax, Inc. announced that the Company's double-blind, randomized, placebo controlled, CHASE clinical trial was initiated in September 2018 and is currently enrolling subjects. The clinical trial is evaluating the effect of low-dose and high-dose ZanthoSyn® on cardiovascular inflammatory health, as measured by high sensitivity C-Reactive Protein (hsCRP), over 12 weeks in subjects with documented cardiovascular risk factors. The study will also include an optional open label extension through 48 weeks. Positive results from this clinical trial, if achieved, could help to: Drive scientific and consumer awareness of ZanthoSyn®'s health benefits. Support additional patent filings. Serve as proof of concept for astaxanthin Rx program. The Company's pharmaceutical development plans for CDX-101 and CDX-301 are underway: CDX-101 is being developed for cardiovascular inflammation and dyslipidemia. The Company believes that an initial indication of severe hypertriglyceridemia provides an efficient clinical pathway to drug approval for CDX-101. CDX-101 is currently in pre-clinical development, including the planning of IND enabling studies. An Investigational New Drug, or IND, must be submitted to the FDA and become effective before clinical trials with a pharmaceutical candidate can begin.CDX-301 is being developed for macular degeneration. The Company believes that an initial indication of Stargardt disease (juvenile macular degeneration) provides an efficient clinical pathway to drug approval for CDX-301.